Novel Nabumetone-Chalcone-Based Pyridine Hybrids: Synthesis, Characterization, and Cytotoxic Activity against the A549 Lung Cancer Cell Line and Normal Human Dermal Fibroblasts (HDFn)
Article Sidebar
Main Article Content
Abstract
Background: Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality, necessitating the continuous discovery of targeted therapies.
Aim of the Study: This study aimed to synthesize and characterize six novel nabumetone-derived heterocyclic compounds (4-9) by integrating chalcone derivatives with pyridine-derived scaffolds and evaluate their cytotoxic activity.
Materials and Methods: The structures of these compounds were validated by Infrared Spectroscopy, Proton Nuclear Magnetic Resonance (1H-NMR), and Carbon Nuclear Magnetic Resonance (13C-NMR) Spectroscopy. All substances were evaluated for their capacity to inhibit cancer cells via the MTT assay in the A549 lung cancer cell line and normal human dermal fibroblasts (HDFn). We established the IC50 values for all drugs using a 48-hour incubation period.
Results: The para-pyridone compound )6 (had the highest cytotoxicity against cancer cells (31.82 µg/mL), whereas the meta-pyridine compound (8) also showed significant cytotoxicity (38.09 µg/mL). Compound (6) exhibited biological activity that surpassed that of the reference medication, Erlotinib, a contemporary chemotherapeutic agent (34.10 µg/mL). Furthermore, both compounds (6) and (8) had considerable Selectivity Indices (SI: 4.92 and 3.90, respectively).
Discussion: Our research demonstrates that both the fundamental architecture of each chemical and the locations of its functional groups are crucial in influencing its biological activity.
Conclusion: These findings suggest that both substituted pyridone cores and substituted 2-aminopyridine cores may serve as promising scaffolds for further optimization and biological evaluation.
Article Details
Section
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
References
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63. DOI: https://doi.org/10.3322/caac.21834
2. Vicidomini G. Current challenges and future advances in lung cancer: Genetics, instrumental diagnosis and treatment. Vol. 15, Cancers. MDPI; 2023. p. 3710. DOI: https://doi.org/10.3390/cancers15143710
3. Smolarz B, Łukasiewicz H, Samulak D, Piekarska E, Kołaciński R, Romanowicz H. Lung cancer—epidemiology, pathogenesis, treatment and molecular aspect (review of literature). Int J Mol Sci. 2025;26(5):2049. DOI: https://doi.org/10.3390/ijms26052049
4. Leone GM, Scuderi G, Fagone P, Mangano K. Directions of Immunotherapy for Non-Small-Cell Lung Cancer Treatment: Past, Present and Possible Future. Int J Mol Sci. 2025;26(22):11055. DOI: https://doi.org/10.3390/ijms262211055
5. Vincent T, Sakthivel KM, Josephine CMR, Prasad R, Chinnadurai K, Kumar P, et al. Mechanistic insights into molecular targeted therapy and immunotherapy for lung cancer. Biochem Biophys Res Commun. 2025; 776:152204. DOI: https://doi.org/10.1016/j.bbrc.2025.152204
6. Roskoski Jr R. Properties of FDA-approved small molecule protein kinase inhibitors: a 2026 update. Pharmacol Res. 2026;108107. DOI: https://doi.org/10.1016/j.phrs.2026.108107
7. Roskoski R. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. Pharmocol Res. 2020; 152:104609. Available from: https://www.sciencedirect.com/science/article/pii/S1043661819328890 DOI: https://doi.org/10.1016/j.phrs.2019.104609
8. K. Bhanumathy K, Balagopal A, Vizeacoumar FS, Vizeacoumar FJ, Freywald A, Giambra V. Protein tyrosine kinases: their roles and their targeting in leukemia. Cancers (Basel). 2021;13(2):184. DOI: https://doi.org/10.3390/cancers13020184
9. Saraon P, Pathmanathan S, Snider J, Lyakisheva A, Wong V, Stagljar I. Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches. Oncogene. 2021;40(24):4079–93. DOI: https://doi.org/10.1038/s41388-021-01841-2
10. Kumar R, Goel H, Solanki R, Rawat L, Tabasum S, Tanwar P, et al. Recent developments in receptor tyrosine kinase inhibitors: A promising mainstay in targeted cancer therapy. Med Drug Discov. 2024;23:100195. DOI: https://doi.org/10.1016/j.medidd.2024.100195
11. Combarel D, Dousset L, Bouchet S, Ferrer F, Tetu P, Lebbe C, et al. Tyrosine kinase inhibitors in cancers: Treatment optimization–Part I. Crit Rev Oncol Hematol. 2024; 199:104384. DOI: https://doi.org/10.1016/j.critrevonc.2024.104384
12. Deshmukh VG, Sapkal SB, Gadekar SS, Deshmukh V. EGFR inhibitors across generations: Progress, challenges, and future directions. J Mol Struct. 2025; 1339:142326. DOI: https://doi.org/10.1016/j.molstruc.2025.142326
13. Bordet C, Dongay V, Zelmat Y, Mazieres J, Despas F. Protein Kinase Inhibitors Indicated for Lung Cancer: Pharmacodynamics, Pharmacokinetics, Adverse Drug Reactions, and Evaluation in Clinical Trials. J Clin Pharm Ther. 2024;2024(1):5437090. Available from: https://doi.org/10.1155/2024/5437090 DOI: https://doi.org/10.1155/2024/5437090
14. Matsumoto K, Hasegawa T, Ohara K, Takei C, Kamei T, Koyanagi J, et al. A metabolic pathway for the prodrug nabumetone to the pharmacologically active metabolite, 6-methoxy-2-naphthylacetic acid (6-MNA) by non-cytochrome P450 enzymes. Xenobiotica. 2020;50(7):783–92. DOI: https://doi.org/10.1080/00498254.2019.1704097
15. Roy HK, Karoski WJ, Ratashak A, Smyrk TC. Chemoprevention of intestinal tumorigenesis by nabumetone: induction of apoptosis and Bcl-2 downregulation. Br J Cancer. 2001;84(10):1412–6. DOI: https://doi.org/10.1054/bjoc.2001.1807
16. Alawad KM, Mahdi MF, Raauf AMR. Molecular Docking study, and In vitro Evaluation of Antitumor Activity of Some New Isoxazoline and Pyrazoline Derivatives of Nabumetone against breast cancer cell line (MCF-7). Al Mustansiriyah Journal of Pharmaceutical Sciences. 2022;22(3):24–34. DOI: https://doi.org/10.32947/ajps.v22i3.886
17. Jameel BK, Raauf AMR, Abbas WAK. Synthesis, characterization, molecular docking, in silico ADME study, and in vitro cytotoxicity evaluation of new pyridine derivatives of nabumetone. Al Mustansiriyah Journal of Pharmaceutical Sciences. 2023;23(3):250–62. DOI: https://doi.org/10.32947/ajps.v23i3.1042
18. Kadhim AH, Mahdi MF, Raauf AMR. Design, Molecular Docking, Synthesis, and Pharmacological Evaluation of Nabumetone-Derived Oxadiazole and Thiadiazole Schiff Bases as Potential EGFR Inhibitors for NSCLC. Al Mustansiriyah Journal of Pharmaceutical Sciences. 2025;25(5):973–91. DOI: https://doi.org/10.32947/ajps.v25i5.1318
19. Meenatchi V, Kim S, Won SY, Buvaneswari K, Han SS. Synthesis, nonlinear optical activity, solvents effect, β-cyclodextrin effect, and cytotoxic activity on skin fibroblast and breast cancer cell lines of a new chalcone derivative of nabumetone. Spectrochim Acta A Mol Biomol Spectrosc. 2025; 325:125148. DOI: https://doi.org/10.1016/j.saa.2024.125148
20. Mallia A, Sloop J. Advances in the synthesis of heteroaromatic hybrid chalcones. Molecules. 2023;28(7):3201. DOI: https://doi.org/10.3390/molecules28073201
21. Donaire-Arias A, Poulsen ML, Ramón-Costa J, Montagut AM, Estrada-Tejedor R, Borrell JI. Synthesis of chalcones: an improved high-yield and substituent-independent protocol for an old structure. Molecules. 2023;28(22):7576. DOI: https://doi.org/10.3390/molecules28227576
22. Al-Masri E, Al-Refai M, Al-Masri HT, Ali BF, Makhseed S, Salah L, et al. Synthesis, characterization, crystal structure, and fluorescence behavior of new 4-aryl-6-(2, 5-dichlorothiophen-3-yl)-2-methylpyridine-3-carbonitrile derivatives. J Mol Struct. 2023; 1271:134034. DOI: https://doi.org/10.1016/j.molstruc.2022.134034
23. Sadallah N, Charif IE, Chemouri H. Theorectical Study of Tautomerism, Physicochemical and ADMET Properties of 2-Pyridone Derivatives. Theoretical Foundations of Chemical Engineering. 2023;57(Suppl 1): S102–9. DOI: https://doi.org/10.1134/S0040579523070126
24. Islam MB, Islam MI, Nath N, Emran T Bin, Rahman MR, Sharma R, et al. Recent advances in pyridine scaffold: focus on chemistry, synthesis, and antibacterial activities. Biomed Res Int. 2023;2023(1):9967591. DOI: https://doi.org/10.1155/2023/9967591
25. Wang S, Yuan X-H, Wang S-Q, Zhao W, Chen X-B, Yu B. FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application. Eur J Med Chem. 2021; 214:113218. DOI: https://doi.org/10.1016/j.ejmech.2021.113218
26. Sanchez RI, Fillgrove KL, Yee KL, Liang Y, Lu B, Tatavarti A, et al. Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans. Xenobiotica. 2019;49(4):422–32. DOI: https://doi.org/10.1080/00498254.2018.1451667
27. Lin S, Liu C, Zhao X, Han X, Li X, Ye Y, et al. Recent advances of pyridinone in medicinal chemistry. Front Chem. 2022; 10:869860. DOI: https://doi.org/10.3389/fchem.2022.869860
28. Fier PS, Kim S, Cohen RD. A multifunctional reagent designed for the site-selective amination of pyridines. J Am Chem Soc. 2020;142(19):8614–8. DOI: https://doi.org/10.1021/jacs.0c03537
29. Yousif OA, Mahdi MF, Raauf AMR. Design, synthesis, preliminary pharmacological evaluation, molecular docking and ADME studies of some new pyrazoline, isoxazoline and pyrimidine derivatives bearing nabumetone moiety targeting cyclooxygenase enzyme. Journal of Contemporary Medical Sciences. 2019;5(1). DOI: https://doi.org/10.22317/jcms.v5i1.521
30. Karim HA, Raauf AM, Ali KF. Synthesis and preliminary pharmacological evaluation of some new triazole derivatives bearing nabumetone moiety targeting cyclooxygenase enzyme. Systematic Reviews in Pharmacy. 2021;12(1):190–5.
31. Bass AKA, Nageeb E-SM, El-Zoghbi MS, Mohamed MFA, Badr M, Abuo-Rahma GE-DA. Utilization of cyanopyridine in design and synthesis of first-in-class anticancer dual acting PIM-1 kinase/HDAC inhibitors. Bioorg Chem. 2022; 119:105564. DOI: https://doi.org/10.1016/j.bioorg.2021.105564
32. Sangwan S, Yadav N, Kumar R, Chauhan S, Dhanda V, Walia P, et al. A score years’ update in the synthesis and biological evaluation of medicinally important 2-pyridones. Eur J Med Chem. 2022; 232:114199. DOI: https://doi.org/10.1016/j.ejmech.2022.114199
33. Ashmawy FO, Gomha SM, Abdallah MA, Zaki MEA, Al-Hussain SA, El-Desouky MA. Synthesis, in vitro evaluation and molecular docking studies of novel thiophenyl thiazolyl-pyridine hybrids as potential anticancer agents. Molecules. 2023;28(11):4270. DOI: https://doi.org/10.3390/molecules28114270
34. Ismail MMF, Farrag AM, Harras MF, Ibrahim MH, Mehany ABM. Apoptosis: A target for anticancer therapy with novel cyanopyridines. Bioorg Chem. 2020; 94:103481. DOI: https://doi.org/10.1016/j.bioorg.2019.103481
35. Bhat M, Marar T. Cytotoxic Effect of Purified L-asparaginase from Salinicoccus sp. M KJ997975. Int J Curr Microbiol App Sci. 2015; 4:701–12.
36. Sánchez-Díez M, Romero-Jiménez P, Alegría-Aravena N, Gavira-O’Neill CE, Vicente-García E, Quiroz-Troncoso J, et al. Assessment of cell viability in drug therapy: IC50 and other new time-independent indices for evaluating chemotherapy efficacy. Pharmaceutics. 2025;17(2):247. DOI: https://doi.org/10.3390/pharmaceutics17020247
37. Ghasemi M, Turnbull T, Sebastian S, Kempson I. The MTT assay: utility, limitations, pitfalls, and interpretation in bulk and single-cell analysis. Int J Mol Sci. 2021;22(23):12827. DOI: https://doi.org/10.3390/ijms222312827
38. Dotta D, Gastaldi M, Fin A, Barbero N, Barolo C, Cardano F, et al. Chalcone synthesis by Green Claisen–Schmidt reaction in cationic and nonionic micellar media. J Org Chem. 2025;90(8):2915–26. DOI: https://doi.org/10.1021/acs.joc.4c02616
39. Salhi F, Cheikh N, Villemin D, Bar N. Synthesis of 2-aminopyridine lactones and studies of their antioxidant, antibacterial and antifungal properties. Chemistry Proceedings. 2022;6(1):9. DOI: https://doi.org/10.3390/ecsoc-25-11709
40. Gouda M, El‐Ggani G, Berghot M, Khalil A. Synthesis and Antioxidant Activity of Some Novel Nicotinonitrile Derivatives Bearing a Furan Moiety. J Heterocycl Chem. 2019;56. doi: 10.1002/jhet.3584 DOI: https://doi.org/10.1002/jhet.3584